Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma

(2021) Elia Aguado-Fraile et al.   Future Oncology

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

(2020) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data

(2019) Jie Ying et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

(2019) Florian Moik et al.   Scientific Reports

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

(2019) Maeve A Lowery et al.   Lancet Gastroenterology & Hepatology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

(2018) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

(2016) Supriya K. Saha et al.   ONCOLOGIST

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

(2015) Bertrand Brieau et al.   CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-line chemotherapy in advanced biliary cancer: a systematic review

(2014) A. Lamarca et al.   ANNALS OF ONCOLOGY

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

(2014) Supriya K. Saha et al.   NATURE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjusting overall survival for treatment switches: commonly used methods and practical application

(2013) Claire Watkins et al.   PHARMACEUTICAL STATISTICS

Chemotherapy for cholangiocarcinoma: An update

(2013) Natalia Ramírez-Merino   World Journal of Gastrointestinal Oncology

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

(2011) James P Morden et al.   BMC Medical Research Methodology

Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21

(2011) E Friend et al.   BRITISH JOURNAL OF CANCER

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER